Barinthus Biotherapeutics plc. 8-K

What Happened
Barinthus Biotherapeutics plc announced that, on May 20, 2026, its shareholders approved a Scheme of Arrangement and the related Scheme Implementation Proposal to carry the Scheme Transaction into effect. The company held two meetings that day: a Court Meeting (convened with the High Court of Justice in England and Wales) and a General Meeting of ordinary shareholders. All matters submitted to the votes were approved, and the reported voting results are final.

Key Details

• Court Meeting (Scheme Shares): 40,848,893 Scheme Shares were entitled to vote; 24,713,109 were present or represented by valid proxy (quorum). Vote: 24,709,337 For, 3,772 Against — 99.98% in favor by value.
• General Meeting (Ordinary Shares): 40,848,893 Ordinary Shares were entitled to vote; 24,714,119 were present or represented by valid proxy (quorum). Vote: 24,710,187 For, 3,922 Against, 10 Abstain — 99.98% in favor by votes cast.
• The Scheme Implementation Proposal details are in the company’s Proxy Statement filed with the SEC on April 22, 2026.

Why It Matters
Shareholder approval clears a key procedural and legal step so Barinthus can proceed with the Scheme Transaction as described in its proxy materials. For investors, this means the company is moving forward with the agreed transaction process; next steps and timing will depend on any remaining regulatory or court approvals and the implementation timetable disclosed in future filings. Review the April 22, 2026 Proxy Statement and subsequent SEC filings for specifics on transaction terms and the expected timeline.